|drug3231||Standard of care Wiki||0.22|
|D019337||Hematologic Neoplasms NIH||0.38|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
From the end of January 2020, Coronavirus disease 2019 began to spread in United Kingdom (UK). During the same time, seasonal flu continued to circulate across the UK. With similar course of management at early stages, flu like symptoms were self-isolated to prevent the spread and further complications of infection. Present study aimed to evaluate the effect of self-managed Ayurveda on flu like symptoms in people who self-isolated at home for 7-days in March 2020 during the Covid-19 outbreak in UK.
Description: Time to bring down a fever (oral temperature < 37.2˚C)Measure: Time to achieve afebrile Time: From Baseline to 3rd and 7th-days of intervention
Description: Symptoms diary card completed twice daily from Day 0 to Day 7Measure: Severity of influenza symptom score Time: Twice daily from Day 1 to Day 7
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports